Virbac

Virbac SA is the sixth-largest pure-play animal-health company in the world, headquartered in Carros near Nice, France, founded in 1968 by Pierre-Richard Dick. The Dick family still holds approximately 60 percent of the share capital through Panpharma Investments — multi-generational French family control of a pet-healthcare compounder. Revenue 1.46 billion EUR FY2025 (4.6 percent year-over-year), operating margin 13.5 percent, ROE 13.9 percent, earnings growth 35.2 percent — the earnings acceleration in 2025 is the story.

At 350 EUR, the stock trades at the 57.8th percentile of its 52-week range (low 296, high 389.5). Trailing P/E 19.5, forward P/E 15.2, P/S 2.0, EV/EBITDA 10.9, free cash flow 127 million EUR. Debt-to-equity at 25.8 percent — moderate leverage, the kind that supports patient capital expansion rather than financial-engineering risk. The 0.41 percent dividend yield reflects an 8 percent payout ratio — Virbac is reinvesting cash into product development and emerging-market expansion, not returning to shareholders.

The structural story is pet humanization. Global pet-healthcare spending grew from 25 billion USD in 2015 to 42 billion in 2025 — a 5.3 percent CAGR through inflation cycles, COVID, and consumer recession. Pet parents treat dogs and cats as family members; veterinary clinics increasingly offer human-grade diagnostics, oncology, surgical robotics, and chronic-disease management. The big four global animal-health leaders (Zoetis, Boehringer Vetmedica, Merck Animal Health, Elanco) trade at premium multiples (Zoetis at 28x forward, the others 18 to 24x). Virbac at 15.2x forward is the cheapest top-six pure-play in the sector.

Analyst consensus 413 EUR price target (9 covering names, Buy rating) — 18 percent upside. The setup is not a deep-value-cycle-bottom story like Krones — it is a quality-growth-at-a-reasonable-price story with structural tailwind and family-control discipline.

The Dick family controls approximately 60 percent of share capital through Panpharma Investments. This is one of the longest-tenured French family holdings in healthcare — Pierre-Richard Dick founded the company in 1968 and the family has never sold a controlling stake. The remaining 40 percent free-float is dominated by European specialist healthcare funds: Amundi Asset Management (3.9 percent), BNP Paribas Asset Management (2.8 percent), Comgest (2.4 percent), Eurazeo Investment Manager (1.7 percent). Comgest in particular is the European-quality-growth investor whose presence signals long-only patient-capital ownership at the institutional level.

Short interest is zero — there is no concentrated short thesis. Volume profile shows steady institutional accumulation through 2025 in the 320 to 360 EUR range; the Q1 2025 earnings beat (operating margin jumped from 10.8 to 13.5 percent) was the inflection that brought in factor-rotation buying. The family-control structure makes a hostile-takeover scenario essentially impossible, but a strategic-partnership deal with one of the big four (most likely Boehringer or Merck Animal Health) at a 30 to 40 percent premium would require family approval at fair valuation — a real but uncertain upside scenario.

At 350 EUR Virbac trades on 19.5x trailing P/E, 15.2x forward P/E, 2.0x sales, 2.6x book, and 10.9x EV/EBITDA. Free cash flow yield is 4.3 percent on the equity. The metrics are fair-to-attractive for a quality specialty healthcare with growth.

Three valuation paths. (1) Multiple convergence to Elanco at 18x forward P/E without further earnings improvement — 410 EUR per share, 17 percent upside; (2) Earnings growth to 22 EUR EPS in 2027 (operating margin 15 percent on 5 percent revenue growth) at 16x P/E — 352 EUR per share, in line with today plus dividend; (3) Multiple expansion to 20x plus EPS growth to 25 EUR by 2028 — 500 EUR per share, 43 percent upside over 3 years. Analyst consensus 413 EUR aligns with the multiple-convergence path. The high-end target of 440 EUR adds modest earnings-growth contribution.

1. Q1 2026 results (April 2026):

   Operating margin sustaining above 13 percent and companion-animal organic growth above 7 percent. Confirms the mix-shift thesis is durable.

2. Capital Markets Day H1 2026:

   Management has indicated a refreshed medium-term framework. Formal 15 to 16 percent operating margin target by 2028 unlocks institutional re-rating.

3. Bidder approach from Boehringer or Merck:

   Speculative — both have approached the family before. A 30 to 40 percent premium offer would force the Dick family to decide. Timing unpredictable, but the family is getting older (second-generation transition) and the strategic-fit logic is compelling.

Virbac is a classic French Mittelstand family compounder in a structurally growing end-market. The pet-humanization tailwind gives you secular demand independent of cycle. The 60 percent family ownership gives you patient capital and a real moat against quarterly-pressure short-term thinking. The 15.2x forward P/E gives you valuation upside even if growth merely matches expectations. The margin-inflection in 2025 from 10.8 to 13.5 percent operating margin is the kind of structural story that re-rates over 24 to 36 months as the institutional market gradually accepts it.

I would size this at 2 to 3 percent of portfolio with a 24 month horizon and a 295 EUR stop-loss (1 percent below the 52-week low). Upside scenarios cluster at 410 to 460 EUR; downside at 280 to 295. Asymmetry is roughly 3-to-1 favorable. The risk-reward is similar to GN.CO and Stevanato — quality compounder at a reasonable price with family-control discipline. A good portfolio sleeve in European specialty healthcare.